Albanese A, Stanhope R
Great Ormond Street Hospital for Children, NHS Trust, London, UK.
Horm Res. 1997;48(4):173-7. doi: 10.1159/000185509.
The anthropometric response to 7 years of GH treatment was assessed in 11 short children with Russell-Silver syndrome (RSS) and in 5 with non-dysmorphic intrauterine growth retardation (NRSS). GH treatment induced a significant increase (p < 0.0001) in the mean height standard deviation score (SDS) and at the 7-year follow-up a height appropriate for the natural history of final stature in NRSS/RSS was already attained. An appreciable growth rate was still present with final height being attained only in 2 girls. There was no significant change in height SDS for bone age. Multiple regression analysis showed only chronological age at the onset of GH treatment was a predictor of gain in height SDS during GH therapy. These findings suggest that early GH treatment improves long-term growth in children with NRSS/RSS. Moreover, final height attainment is required for a definitive assessment of the beneficial effect on adult stature. Bone age assessment is not a reliable parameter to predict final height outcome in these children.
对11名患有罗素-西尔弗综合征（RSS）的矮小儿童和5名非畸形性宫内生长迟缓（NRSS）儿童进行了为期7年的生长激素（GH）治疗的人体测量反应评估。GH治疗使平均身高标准差评分（SDS）显著增加（p < 0.0001），并且在7年随访时，NRSS/RSS患儿已达到适合其最终身高自然史的身高。仍存在可观的生长速率，仅2名女孩达到了最终身高。骨龄的身高SDS没有显著变化。多元回归分析显示，仅GH治疗开始时的实足年龄是GH治疗期间身高SDS增加的预测指标。这些发现表明，早期GH治疗可改善NRSS/RSS儿童的长期生长。此外，需要达到最终身高才能明确评估对成人身高的有益效果。骨龄评估不是预测这些儿童最终身高结果的可靠参数。
